Background/Aim: The guidelines of the British Photodermatology Group for topical treatment with psoralen and ultraviolet light (PUVA) recommend starting UVA doses between 0.2 and 0.5 J/cm2, according to the phototype. Our purpose was to evaluate the therapeutic efficacy and tolerability of bath PUVA, with 8-methoxypsoralen (8-MOP), by using lower UVA doses, regardless of phototype. Methods: We compared 2 groups of patients (group 1: n = 10, group 2: n = 20) with chronic plaque-type psoriasis. Group 1 was treated with the usual starting dose and dose progression; group 2 was treated by using a lower first dose, a slower dose progression and reaching a lower maximum dose. The Psoriasis Area and Severity Index (PASI) score was assessed at the initial stages, and every month until the end of the treatment. Results: In group 1, the median baseline PASI score decreased from 15.2 to 4.5 (p < 0.005, Student’s paired t test), while in group 2, it fell from 13.7 to 4.1 (p < 0.005). No statistical difference between the groups is detectable. Severe phototoxic reactions were observed only in 2 patients of group 1. Side effects were not observed in group 2. Conclusions: Our data indicate that an aggressive bath PUVA treatment is not substantially more effective in clearing chronic plaque-type psoriasis than a milder therapeutic approach.

Keywords:
Photochemotherapy, Psoriasis, Bath PUVA, UVA dose
1.
Schiener R, Behrens-Williams SC, Pillekamp H, Peter RU, Kerscher M: Does the minimal phototoxic dose after 8-methoxypsoralen baths correlate with the individual’s skin phototype? Photodermatol Photoimmunol Photomed 2001;17:156–158.
2.
Halpern SM, Anstey AV, Dawe RS, Diffey BL, Farr PM, Ferguson J, et al: Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. Br J Dermatol 2000;142:22–31.
3.
Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL: Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68:328–335.
4.
Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Berne B: Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA. A preliminary report. Arch Dermatol 1992;128:1341–1344.
5.
Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, Lindelof B, Berne B, Hannuksela M, Poikolainen K, Karvonen J: Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. J Am Acad Dermatol 1996;35:685–689.
6.
Hannuksela-Svahn A, Pukkala E, Koulu L, Jansen CT, Karvonen J: Cancer incidence among Finnish psoriasis patients treated with 8-methoxypsoralen bath PUVA. J Am Acad Dermatol 1999;40:694–696.
7.
Karrer S, Eholzer C, Ackermann G, Landthaler M, Szeimies RM: Phototherapy of psoriasis: comparative experience of different phototherapeutic approaches. Dermatology 2001;202:108–115.
8.
Nijsten T, Lambert J: Dermatologists’ views and opinions about photo(chemo)therapy and conventional systemic psoriasis therapies: results from a Belgian survey. Dermatology 2006;213:123–133.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.